{"url_path":"/sec/sgmo/8-k/2026-02-04/item-3-02","section_key":"item-3-02","section_title":"Item 3.02 Unregistered Sales of Equity Securities.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-02-04","source_url":"https://www.sec.gov/Archives/edgar/data/1001233/0001193125-26-036792-index.html","accession_number":"0001193125-26-036792","cik":"0001001233","ticker":"SGMO","issuer_name":"SANGAMO THERAPEUTICS, INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1001233/0001193125-26-036792-index.html","primary_entity_key":"0001001233","primary_entity_name":"SANGAMO THERAPEUTICS, INC"},"word_count":198,"has_tables":true,"body_markdown":"Item 3.02 Unregistered Sales of Equity Securities.\n\nThe information set forth in Item 1.01 of this Current Report on Form 8-K relating to the Warrant Amendment is incorporated by reference herein. The Warrant Amendment may be deemed to involve an exchange of securities exempt from registration pursuant to Section 3(a)(9) of the Securities Act.\n\nForward-Looking Statements\n\nThis report contains forward-looking statements, including, without limitation, statements relating to Sangamo’s expectations regarding the completion of the Offering. These forward-looking statements are based upon Sangamo’s current expectations. Actual results could differ materially from these forward-looking statements as a result of certain factors, including, without limitation, risks and uncertainties related to the satisfaction of customary closing conditions related to the Offering and other risks detailed in Sangamo’s filings with the SEC, including Sangamo’s Annual Report on Form 10-K for the year ended December 31, 2024, Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 and in the prospectus supplement relating to the offering. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. Sangamo undertakes no duty to update such information except as required under applicable law."}